Siglec-5 and Siglec-14 Paired Receptor Architecture in Monocytic Lineages
Human monocytic lineages express paired sialic acid-binding immunoglobulin-like lectin (Siglec) receptors that calibrate myeloid activation thresholds [1]. Among these paired structures, Siglec-5 (CD170) and Siglec-14 display near-identical extracellular V-set and C2-set immunoglobulin domains, conferring shared binding affinity for α-2,3- and α-2,6-linked sialic acid glycans [1]. Divergence resides within their membrane and cytoplasmic topologies. Siglec-5 functions as an inhibitory receptor harboring two cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Ligand engagement induces phosphorylation of these motifs, facilitating the recruitment and enzymatic activation of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and SHP-2 [1][2]. This phosphatase recruitment attenuates kinase cascades downstream of pattern recognition receptors, enforcing immune quiescence [2].
In contrast, Siglec-14 lacks intrinsic intracellular signaling motifs. It possesses an arginine residue within its transmembrane domain that couples with the immunoreceptor tyrosine-based activation motif (ITAM)-bearing adaptor molecule DAP12 (TYROBP) [1]. Upon ligand recognition, DAP12 recruits spleen tyrosine kinase (SYK), initiating pro-inflammatory transcriptional and post-translational cascades. Human populations display balanced evolutionary polymorphism: a substantial deletion allele (SIGLEC14*null) eliminates Siglec-14 expression, leaving homozygous individuals dependent exclusively on the inhibitory Siglec-5 receptor [1]. Consequently, baseline myeloid reactivity to pharmacological perturbations is conditioned by this paired receptor architecture [1][3]. In the THP-1 monocyte line, both paired receptors are expressed, providing an established model to interrogate receptor balance [1].
Table 1 benchmarks the pharmacological parameters, core affinities, and operational signaling readouts of tamoxifen alongside benchmark selective estrogen receptor modulators (SERMs) and pure estrogen receptor down-regulators (SERDs).
Tamoxifen-Driven Alteration of the Siglec-5/Siglec-14 Surface Equilibrium
Treatment of primary human CD14+ monocytes and monocytic lines with tamoxifen triggers an ERα- and ERβ-independent shift in paired checkpoint presentation [1][4]. Flow cytometric profiling utilizing receptor-specific monoclonal antibodies—clone 1A5 for Siglec-5 and clone 3A8 for Siglec-14—reveals a concentration-dependent down-regulation of cell-surface Siglec-5 [1]. Across an exposure range of 2.5 µM to 7.5 µM tamoxifen, surface Siglec-5 mean fluorescence intensity decreases by 42% to 68% relative to vehicle-treated controls (0.1% DMSO) [1]. Conversely, cell-surface presentation of activating Siglec-14 remains preserved or moderately up-regulated [1]. This dynamic alters the Siglec-14:Siglec-5 surface ratio in favor of activating signaling complexes [1].
This balance shift is not recapitulated by the selective estrogen receptor down-regulator (SERD) fulvestrant (ICI 182,780) at saturating concentrations (1 µM to 10 µM), confirming that checkpoint modulation operates via non-canonical signaling routes independent of nuclear estrogen receptor engagement [1][4]. Furthermore, co-treatment of monocytes with fulvestrant does not block tamoxifen-induced Siglec-5 down-regulation [1]. Biophysical assessments indicate that tamoxifen, characterized by its lipophilic triphenylethylene core, intercalates into cholesterol-rich membrane microdomains [4]. This membrane perturbation alters the lateral mobility and clustering kinetics of sialic acid-binding lectins [1][4]. As a result, Siglec-5 undergoes accelerated endocytosis and lysosomal degradation, whereas Siglec-14 is stabilized at the plasma membrane through its transmembrane association with the DAP12 scaffold [1]. These receptor alterations occur without inducing cell death, provided concentrations remain below 10 µM, as confirmed by minimal lactate dehydrogenase release into the culture supernatant [4].
DAP12 Phosphorylation and SYK-Dependent NLRP3 Priming
The selective persistence and clustering of Siglec-14 initiates transmembrane activation cascades [1]. Immunoblotting and phospho-specific flow cytometry reveal rapid phosphorylation of the DAP12 ITAM domain at residues Tyr-65 and Tyr-76 within 30 to 90 minutes of tamoxifen exposure [1]. Phosphorylated Tyr-65 and Tyr-76 form high-affinity docking sites for the tandem SH2 domains of spleen tyrosine kinase (SYK), recruiting this cytosolic kinase to the inner leaflet of the plasma membrane [1]. Once localized, SYK undergoes autophosphorylation at Tyr-525 and Tyr-526 within its activation loop, elevating its intrinsic phosphotransferase activity [1].
Pre-treatment of monocytes with the selective SYK inhibitor R406 (300 nM) suppresses downstream signaling, confirming the kinase dependency of this pathway [1]. Downstream of active SYK, monocytic cells display elevated production of mitochondrial reactive oxygen species (ROS) and a measured efflux of intracellular potassium (K+) [4]. These intracellular perturbations drive transcriptional priming of the NLRP3 inflammasome complex [4]. Quantitative real-time PCR demonstrates a 4.2-fold elevation in NLRP3 mRNA levels alongside a 6.8-fold induction of pro-IL-1β (IL1B) transcripts following 4 to 8 hours of exposure to 5 µM tamoxifen [1][4]. Nuclear translocation of the NF-κB p65 subunit coordinates this transcriptional response, linking the altered Siglec surface checkpoint to inflammatory machinery [4][5].
Caspase-1 Cleavage Kinetics and Proteolytic Maturation of IL-1β and TNF-α
Following SYK-dependent priming and cellular ion shifts, the nucleocytoplasmic adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD) undergoes macromolecular assembly into cytosolic specks [4]. This provides a molecular platform for the recruitment and activation of pro-caspase-1 [4]. Time-resolved immunoblotting reveals the temporal cleavage kinetics of the 45 kDa pro-caspase-1 zymogen. Initial processing yields the intermediate p35 fragment within 4 hours, resolving into enzymatically active p20 and p10 heterodimers across a 6- to 24-hour treatment window [4].
Active caspase-1 complexes catalyze the proteolytic maturation of the 31 kDa pro-IL-1β precursor, cleaving the peptide backbone at the Asp116–Ala117 peptide bond to generate biologically active 17 kDa IL-1β [4]. Multiplex bead array profiling and homogeneous time-resolved fluorescence (HTRF) assays demonstrate significant accumulation of mature IL-1β in monocyte supernatants, reaching concentrations between 140 pg/mL and 380 pg/mL following 16 hours of 5 µM tamoxifen treatment [1][4]. Concurrently, secretome analysis detects de novo secretion of TNF-α (450 pg/mL to 920 pg/mL), driven by transcriptional activation downstream of SYK-dependent cascades [1][5].
To establish target specificity, pharmacological inhibition of caspase-1 with VX-765 (belnacasan, 10 µM) reduces active 17 kDa IL-1β secretion by >90% without impairing TNF-α release, isolating the proteolytic checkpoint [4]. Conversely, functional neutralization of cell-surface Siglec-14 utilizing receptor-specific F(ab')2 fragments abrogates both caspase-1 cleavage and cytokine secretion, confirming that downstream inflammatory activation is initiated through the Siglec-14/DAP12 axis [1].
Myeloid Reprogramming in Immunologically Cold Microenvironments
Beyond cytokine secretion, tamoxifen-mediated modulation of the Siglec-5/14 axis reprograms monocytic polarization states within immunosuppressive microenvironments [1][2]. In primary human CD14+ monocytes exposed to immunosuppressive conditioning media, cells typically adopt a CD206(high)IL-10(high) phenotype characteristic of suppressive myeloid-derived cells and M2 macrophages [2][6]. Treatment with tamoxifen (2.5 µM to 5 µM) counters this polarization, down-regulating CD206 surface expression by 54% while attenuating immunosuppressive IL-10 secretion [1][2]. Concurrently, the monocytes up-regulate antigen-presentation markers, achieving high surface densities of CD86 and HLA-DR [2][7].
In cellular co-culture systems incorporating the RAW 264.7 macrophage line alongside breast adenocarcinoma models, tamoxifen suppresses tumor-promoting macrophage migration and prevents the establishment of a tolerogenic niche by disrupting SHP-1/SHP-2-mediated checkpoint signaling [6][7]. This myeloid repolarization is relevant to cold tumor microenvironments dominated by immunosuppressive myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), where conventional immune checkpoint inhibitors often fail [2][3].
Evaluation of active tamoxifen metabolites reveals distinct pharmacodynamic potencies [1]. Both 4-hydroxytamoxifen (4-OHT) and endoxifen (N-desmethyl-4-hydroxytamoxifen) trigger paired Siglec-5/14 axis remodeling and subsequent cytokine maturation at lower concentrations (0.5 µM to 2 µM) than the parent compound, correlating with their elevated affinity for lipophilic targets and cellular membranes [1][4]. In vivo studies utilizing TSAE1-bearing mice corroborate systemic shifts in myeloid compartments following tamoxifen administration, showing alterations in non-classical monocytes and dendritic cell activation profiles [5]. Modulating myeloid Siglec checkpoints via non-canonical small-molecule signaling offers an empirical foundation for reprogramming immunosuppressive myeloid niches [1][2][5].